# DoD Awards $41M Wafermine Contract

The U.S. Department of Defense awarded iX Biopharma a US$41 million contract in February 2026 to develop Wafermine, a ketamine-based pain treatment for military use, including emergency-use authorization work and clinical trials. iX says the contract is separate from its proposed manufacturing joint venture with Orion Specialty Labs, so Orion’s pending Nevada state licence does not affect the DoD award. The work carries schedule and cash-flow risks: reimbursement follows costs already incurred, and iX has shifted its expected emergency-use submission from Q4 2026 to within the next 12 months.

- **Why this matters:** Contractors and suppliers supporting the work should distinguish the DoD-funded development scope from the proposed Orion manufacturing arrangement; the company says the pending state licence does not affect the contract.
- Because reimbursement follows incurred costs, iX may need to finance work before receiving payment, making cash-flow capacity relevant to delivery planning and subcontractor arrangements.
- The revised submission timing and clinical-trial work indicate that schedule and regulatory milestones remain material to the development effort.

**Jurisdictions:** federal
**Industries:** Healthcare, Defense & Military
**Topics:** Regulatory Compliance
**Published:** November 05, 2026

### Government Entities
- U.S. Department of Defense (DoD)
- U.S. Food and Drug Administration (FDA)
- Nevada state licensing authority

### Vendors
- iX Biopharma (awardee)
- Orion Specialty Labs (prospective manufacturing partner)

### Sources
- [iX Biopharma clarifies US manufacturing partner’s licence, says US$41m Pentagon ketamine wafer deal unaffected | The Straits Times](https://www.straitstimes.com/business/ix-biopharma-replies-sgx-queries-on-partners-licence-says-us41m-pentagon-ketamine-wafer-deal) - The Straits Times